ArticleScientific reports2018
Extracellular vesicles are associated with the systemic inflammation of patients with seropositive rheumatoid arthritis.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The role of extracellular vesicles in rheumatoid arthritis: a systematic review.Clinical rheumatology · 2021Pooled it
- Aggrecan and polymeric immunoglobulin receptor in extracellular vesicles of patients with seropositive rheumatoid arthritis.Journal of translational autoimmunity · 2026Article
- Glycosylation of Extracellular Vesicles: Analytical and Translational Insights into Biomarker Discovery and Regenerative Medicine.International journal of molecular sciences · 2026Review
- Extracellular vesicles in rheumatoid arthritis: emerging roles in progression, diagnosis, and therapeutic development.Frontiers in immunology · 2026Review
- Exosomal Protein Biomarkers in Arthritis: Deciphering the Inflammatory Profiles of RA and OA.Biomedicines · 2025Article
- Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes.Scientific reports · 2025Article
- Exosomal miRNAs involvement in pathogenesis, diagnosis, and treatment of rheumatoid arthritis.Heliyon · 2025Review
- Preanalytical framework for routine clinical use of liquid biopsies: combining EVs and cfDNA.Extracellular vesicles and circulating nucleic acids · 2025Article
- Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review.Dentistry review (New York, N.Y.) · 2024Article
- Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype.Lupus science & medicine · 2024Article
- Janus kinase inhibitors modify the fatty acid profile of extracellular vesicles and modulate the immune response.Heliyon · 2024Article
- Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis.Frontiers in immunology · 2024Review
- Diagnostic and Therapeutic Roles of Extracellular Vesicles and Their Enwrapped ncRNAs in Rheumatoid Arthritis.Journal of inflammation research · 2024Review
- Updates on the Pathophysiology and Therapeutic Potential of Extracellular Vesicles with Focus on Exosomes in Rheumatoid Arthritis.Journal of inflammation research · 2024Review
- Review
- Review
- Article
- Extracellular vesicles from human plasma for biomarkers discovery: Impact of anticoagulants and isolation techniques.PloS one · 2023Article
- The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.The Biochemical journal · 2022Review
- Modulation of B cell activation by extracellular vesicles and potential alteration of this pathway in patients with rheumatoid arthritis.Arthritis research & therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with rheumatoid arthritis (RA) and autoantibodies, such as rheumatoid factor and those against cyclic citrullinated peptides, are designated as seropositive and have a more severe disease with worse prognosis than seronegative RA patients. Understanding the factors that participate in systemic inflammation, in addition to articular commitment, would allow better treatment approaches for prevention of RA comorbidities and disease reactivation. We evaluated whether monocyte subsets and extracellular vesicles (EVs) could contribute to this phenomenon. Seropositive patients had higher levels of proinflammatory cytokines than those of seronegative patients and healthy controls (HCs); however, this systemic inflammatory profile was unrelated to disease activity. High frequencies of circulating EVs positive for IgG, IgM, CD41a, and citrulline, together with altered counts and receptor expression of intermediate monocytes, were associated with systemic inflammation in seropositive patients; these alterations were not observed in seronegative patients, which seem to be more similar to HCs. Additionally, the EVs from seropositive patients were able to activate mononuclear phagocytes in vitro, and induced proinflammatory cytokines that were comparable to the inflammatory response observed at the systemic level in seropositive RA patients; therefore, all of these factors may contribute to the greater disease severity that has been described in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.